Fulcrum Therapeutics, Inc. (FULC)

Exchange NASDAQ
5.14


Currency in USD (Disclaimer)
Volume:
Day's Range:

FULC Insider Trading

Transaction Date Reporting Name Relationship Shrs. Owned Type Acq./Disp. Shrs. Transacted Price(USD) Amount(USD) SEC Filing
2022-06-07 Gould Robert J director 86,523.0 M-Exempt D 71,435.0 7.84 560,050.40
2022-06-07 Gould Robert J director 506,630.0 S-Sale D 71,435.0 8.09 577,894.86
2022-06-07 Gould Robert J director 578,065.0 M-Exempt A 71,435.0 7.84 560,050.40
2022-06-06 Gould Robert J director 157,958.0 M-Exempt D 24,382.0 7.84 191,154.88
2022-06-06 Gould Robert J director 182,340.0 M-Exempt D 25,551.0 7.84 200,319.84
2022-06-06 Gould Robert J director 207,891.0 M-Exempt D 16,689.0 7.84 130,841.76
2022-06-06 Gould Robert J director 506,630.0 S-Sale D 24,382.0 8.10 197,591.73
2022-06-06 Gould Robert J director 531,012.0 M-Exempt A 24,382.0 7.84 191,154.88
2022-06-03 Gould Robert J director 506,630.0 S-Sale D 25,551.0 7.95 203,056.35
2022-06-03 Gould Robert J director 532,181.0 M-Exempt A 25,551.0 7.84 200,319.84
2022-06-02 Gould Robert J director 506,630.0 S-Sale D 16,689.0 7.92 132,161.86
2022-06-02 Gould Robert J director 523,319.0 M-Exempt A 16,689.0 7.84 130,841.76
2022-05-06 Tourangeau Greg officer: Controller 6,500.0 A-Award A 6,500.0 8.63 56,095.00
2022-05-06 Tourangeau Greg officer: Controller 16,202.0 A-Award A 3,250.0 0.00 0.00
2022-04-07 Gould Robert J director 224,580.0 M-Exempt D 5,631.0 7.84 44,147.04
2022-04-07 Gould Robert J director 506,630.0 S-Sale D 5,631.0 24.02 135,228.46
2022-04-07 Gould Robert J director 512,261.0 M-Exempt A 5,631.0 7.84 44,147.04
2022-04-05 Gould Robert J director 230,211.0 M-Exempt D 52,552.0 7.84 412,007.68
2022-04-05 Gould Robert J director 282,763.0 M-Exempt D 7,235.0 7.84 56,722.40
2022-04-05 Gould Robert J director 289,998.0 M-Exempt D 34,464.0 7.84 270,197.76
2022-04-05 Gould Robert J director 506,630.0 S-Sale D 52,552.0 24.26 1,274,774.88
2022-04-05 Gould Robert J director 559,182.0 M-Exempt A 52,552.0 7.84 412,007.68
2022-04-04 Gould Robert J director 506,630.0 S-Sale D 7,235.0 24.02 173,749.25
2022-04-04 Gould Robert J director 513,865.0 M-Exempt A 7,235.0 7.84 56,722.40
2022-04-01 Gould Robert J director 506,630.0 S-Sale D 34,464.0 24.03 828,159.58
2022-04-01 Gould Robert J director 541,094.0 M-Exempt A 34,464.0 7.84 270,197.76
2022-01-19 Oltmans Curtis Gale officer: SVP, General Counsel 60,000.0 A-Award A 60,000.0 12.69 761,400.00
2022-01-19 Morabito Christopher officer: Chief Medical Officer 59,744.0 A-Award A 59,744.0 12.69 758,151.36
2022-01-19 Stuart Bryan director, officer: President & Chief Executive Officer 340,000.0 A-Award A 340,000.0 12.69 4,314,600.00
2022-01-19 Dunn Judith officer: President, Research & Development 140,890.0 A-Award A 140,890.0 12.69 1,787,894.10
2022-01-19 Thomson Peter G. officer: VP Finance & Accounting 40,000.0 A-Award A 40,000.0 12.69 507,600.00
2022-01-03 Rajavelu Esther officer: Chief Financial Officer 200,000.0 A-Award A 200,000.0 17.82 3,564,000.00
2021-12-17 Oltmans Curtis Gale officer: SVP, General Counsel 1,248.0 G-Gift D 1,088.0 0.00 0.00
2021-12-08 Banks Sonja director 30,000.0 A-Award A 30,000.0 15.73 471,900.00
2021-11-10 LEVIN MARK J director, 10 percent owner 3,962,202.0 J-Other D 1,000,000.0 0.00 0.00
2021-11-10 Third Rock Ventures III, L.P. 10 percent owner 3,962,202.0 J-Other D 1,000,000.0 0.00 0.00
2021-09-22 LEVIN MARK J director, 10 percent owner 4,962,202.0 J-Other D 1,000,000.0 0.00 0.00
2021-09-22 Third Rock Ventures III, L.P. 10 percent owner 4,962,202.0 J-Other D 1,000,000.0 0.00 0.00
2021-08-11 Stuart Bryan officer: Chief Operating Officer 28,000.0 M-Exempt A 28,000.0 23.75 665,000.00
2021-08-11 Stuart Bryan officer: Chief Operating Officer 0.0 S-Sale D 28,000.0 23.75 665,000.00
2021-08-11 Stuart Bryan officer: Chief Operating Officer 243,571.0 M-Exempt D 28,000.0 23.75 665,000.00
2021-08-10 Stuart Bryan officer: Chief Operating Officer 32,000.0 M-Exempt A 32,000.0 7.84 250,880.00
2021-08-10 Stuart Bryan officer: Chief Operating Officer 0.0 S-Sale D 32,000.0 7.84 250,880.00
2021-08-10 Stuart Bryan officer: Chief Operating Officer 271,571.0 M-Exempt D 32,000.0 7.84 250,880.00
2021-08-10 Moxham Christopher officer: Chief Scientific Officer 20,714.0 M-Exempt A 20,714.0 7.84 162,397.76
2021-08-10 Moxham Christopher officer: Chief Scientific Officer 72,501.0 M-Exempt D 31,071.0 18.00 559,278.00
2021-08-10 Moxham Christopher officer: Chief Scientific Officer 0.0 S-Sale D 20,714.0 7.84 162,397.76
2021-08-10 Moxham Christopher officer: Chief Scientific Officer 31,071.0 M-Exempt A 31,071.0 18.00 559,278.00
2021-08-10 Moxham Christopher officer: Chief Scientific Officer 103,572.0 M-Exempt D 20,714.0 7.84 162,397.76
2021-06-28 GERAGHTY JAMES A director 90,714.0 P-Purchase A 10,000.0 9.16 91,600.00
2021-06-28 Morabito Christopher officer: Chief Medical Officer 1,100.0 P-Purchase A 1,100.0 9.16 10,076.00
2021-06-28 Oltmans Curtis Gale officer: SVP, General Counsel 1,088.0 P-Purchase A 1,088.0 9.01 9,802.88
2021-06-28 Thomson Peter G. officer: VP Finance & Accounting 2,300.0 P-Purchase A 2,300.0 9.00 20,700.00
2021-06-09 GERAGHTY JAMES A director 15,000.0 A-Award A 15,000.0 8.85 132,750.00
2021-06-09 LEVIN MARK J director, 10 percent owner 15,000.0 A-Award A 15,000.0 8.85 132,750.00
2021-06-09 Haviland Kate director 15,000.0 A-Award A 15,000.0 8.85 132,750.00
2021-06-09 Dorton Katina director 15,000.0 A-Award A 15,000.0 8.85 132,750.00
2021-06-09 Ezekowitz Alan director 15,000.0 A-Award A 15,000.0 8.85 132,750.00
2021-06-09 Collins James J. director 15,000.0 A-Award A 15,000.0 8.85 132,750.00
2021-05-10 Morabito Christopher officer: Chief Medical Officer 163,000.0 A-Award A 163,000.0 10.01 1,631,630.00
2021-04-01 Dunn Judith officer: See Remarks 215,000.0 A-Award A 215,000.0 12.00 2,580,000.00
2021-03-31 Stuart Bryan officer: Chief Operating Officer 350,000.0 A-Award A 350,000.0 11.78 4,123,000.00
2021-03-16 Gould Robert J director, officer: See Remarks 506,630.0 S-Sale D 789.0 12.43 9,805.61
2021-03-15 Gould Robert J director, officer: See Remarks 507,419.0 S-Sale D 9,211.0 12.13 111,772.72
2021-02-22 Thomson Peter G. officer: VP Finance & Accounting 15,212.0 S-Sale D 5,000.0 7.84 39,200.00
2021-02-22 Thomson Peter G. officer: VP Finance & Accounting 50,471.0 M-Exempt D 5,000.0 7.84 39,200.00
2021-02-22 Thomson Peter G. officer: VP Finance & Accounting 20,212.0 M-Exempt A 5,000.0 7.84 39,200.00
2021-02-16 Gould Robert J director, officer: See Remarks 516,630.0 S-Sale D 1,673.0 14.56 24,367.08
2021-02-16 Gould Robert J director, officer: See Remarks 518,303.0 S-Sale D 6,542.0 14.19 92,830.33
2021-02-08 Moxham Christopher officer: Chief Scientific Officer 100,000.0 A-Award A 100,000.0 12.60 1,260,000.00
2021-02-02 Gould Robert J director, officer: See Remarks 269,390.0 A-Award A 269,390.0 11.33 3,052,188.70
2021-01-25 Thomson Peter G. officer: VP Finance & Accounting 40,000.0 A-Award A 40,000.0 13.09 523,600.00
2021-01-25 Stuart Bryan officer: Chief Operating Officer 134,376.0 A-Award A 134,376.0 13.09 1,758,981.84
2021-01-21 Thomson Peter G. officer: VP Finance & Accounting 15,212.0 S-Sale D 6,607.0 14.00 92,498.00
2021-01-20 Gould Robert J director, officer: See Remarks 524,845.0 S-Sale D 10,000.0 12.08 120,826.00
2020-12-03 Oltmans Curtis Gale officer: SVP, General Counsel 153,600.0 A-Award A 153,600.0 11.82 1,815,552.00
2020-12-03 Ezekowitz Alan director 15,000.0 A-Award A 15,000.0 11.82 177,300.00
2020-09-14 Wallace Owen B. officer: Chief Scientific Officer 133,438.0 M-Exempt A 6,350.0 7.84 49,784.00
2020-09-14 Wallace Owen B. officer: Chief Scientific Officer 75,592.0 M-Exempt D 6,350.0 7.84 49,784.00
2020-07-08 Gould Robert J director, officer: See Remarks 534,845.0 S-Sale D 2,500.0 20.00 50,000.00
2020-07-08 Wallace Owen B. officer: Chief Scientific Officer 130,039.0 M-Exempt A 2,951.0 7.84 23,135.84
2020-07-08 Wallace Owen B. officer: Chief Scientific Officer 127,088.0 S-Sale D 2,951.0 7.84 23,135.84
2020-07-08 Wallace Owen B. officer: Chief Scientific Officer 81,942.0 M-Exempt D 2,951.0 7.84 23,135.84
2020-07-01 Cadavid Diego officer: SVP Clinical Development 65,714.0 S-Sale D 1,071.0 18.30 19,599.30
2020-06-30 Wallace Owen B. officer: Chief Scientific Officer 127,229.0 M-Exempt A 141.0 7.84 1,105.44
2020-06-30 Wallace Owen B. officer: Chief Scientific Officer 127,088.0 S-Sale D 141.0 7.84 1,105.44
2020-06-30 Wallace Owen B. officer: Chief Scientific Officer 84,893.0 M-Exempt D 141.0 7.84 1,105.44
2020-06-25 Gould Robert J director, officer: See Remarks 537,345.0 S-Sale D 2,500.0 20.80 51,992.00
2020-06-25 Cadavid Diego officer: SVP Clinical Development 68,244.0 M-Exempt A 1,459.0 4.83 7,046.97
2020-06-25 Cadavid Diego officer: SVP Clinical Development 66,785.0 S-Sale D 1,459.0 4.83 7,046.97
2020-06-25 Cadavid Diego officer: SVP Clinical Development 12,277.0 M-Exempt D 1,459.0 4.83 7,046.97
2020-06-11 GERAGHTY JAMES A director 9,285.0 A-Award A 9,285.0 17.63 163,694.55
2020-06-11 LEVIN MARK J director, 10 percent owner 9,285.0 A-Award A 9,285.0 17.63 163,694.55
2020-06-11 Collins James J. director 9,285.0 A-Award A 9,285.0 17.63 163,694.55
2020-06-11 Ezekowitz Alan director 9,285.0 A-Award A 9,285.0 17.63 163,694.55
2020-06-11 Haviland Kate director 9,285.0 A-Award A 9,285.0 17.63 163,694.55
2020-06-10 Cadavid Diego officer: SVP Clinical Development 66,785.0 S-Sale D 401.0 4.83 1,936.83
2020-06-10 Cadavid Diego officer: SVP Clinical Development 13,736.0 M-Exempt D 401.0 4.83 1,936.83
2020-06-10 Cadavid Diego officer: SVP Clinical Development 67,186.0 M-Exempt A 401.0 4.83 1,936.83
2020-06-09 Gould Robert J director, officer: See Remarks 539,845.0 S-Sale D 156.0 20.00 3,120.00

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.